Neurocrine Biosciences, Inc. (NBIX) News

Neurocrine Biosciences, Inc. (NBIX): $102.27

0.48 (+0.47%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Filter NBIX News Items

NBIX News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

NBIX News Highlights

  • 500 - Internal server error
  • Over the past 21 days, the trend for NBIX's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
  • The most mentioned tickers in articles about NBIX are SA.

Latest NBIX News From Around the Web

Below are the latest news stories about Neurocrine Biosciences Inc that investors may wish to consider to help them evaluate NBIX as an investment opportunity.

Subdued Growth No Barrier To Neurocrine Biosciences, Inc.'s (NASDAQ:NBIX) Price

With a price-to-earnings (or "P/E") ratio of 23.4x Neurocrine Biosciences, Inc. ( NASDAQ:NBIX ) may be sending bearish...

Yahoo | June 21, 2021

Idorsia: Putting The Capstone On A Foundationally Strong Biotech

eakrin rasadonyindee/iStock via Getty Images On July 16th, 2019, I shared an article here on SA-" A Swiss Biotech Poised For Fantastic Growth". At the time I wrote this first article about Idorsia (OTCPK:IDRSF) I pointed out that I had identified the potential in the company back in December 2018....

Looking For Diogenes on Seeking Alpha | June 10, 2021

Hematuria Treatment Market 2028 Analysis of Key Players Neurocrine Biosciences, Inc., Pfizer Inc., Biogen Inc., Teva Pharmaceutical Industries Ltd., AcelRx Pharmaceuticals

A new market report by The Insight Partners on the Hematuria Treatment Market has been released with reliable information and accurate forecasts for a better understanding of the current and future market scenarios. The report offers an in-depth analysis of

OpenPR | June 1, 2021

Neurocrine Biosciences to Present at the Goldman Sachs 42nd Annual Global Healthcare Conference

Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the Goldman Sachs 42nd Annual Global Healthcare Conference at 1:20 p.m. Eastern Time on Tuesday, June 8, 2021. Kevin Gorman, Chief Executive Officer, will present at the conference.

BioSpace | May 31, 2021

Neurocrine Biosciences Inc (NBIX): Price Now Near $96.17; Daily Chart Shows Downtrend on 100 Day Basis

Of note is that the 100 day changed directions on nbix; it is now pointing up. The post Neurocrine Biosciences Inc (NBIX): Price Now Near $96.17; Daily Chart Shows Downtrend on 100 Day Basis appeared first on ETF Daily News .

ETF Daily News | May 21, 2021

OBSV Stock: The Big Clinical Trial News Boosting ObsEva Today

Swiss biopharma ObsEva is on course to introduce an oral treatment for uterine fibroids, which affect 80% of women by menopause.

Robert Lakin on InvestorPlace | May 20, 2021

Polycystic Ovary Syndrome Pipeline: Emerging Therapies and Key pharma players involved by DelveInsight | Dexa Medica, Astellas, EffRx, Spruce Biosciences, Neurocrine Biosciences and Others

No summary available.

AB Newswire | May 14, 2021

Texas Permanent School Fund Buys Shares of 70,180 Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

Texas Permanent School Fund bought a new stake in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 70,180 shares of the companys stock, valued at approximately $6,825,000. Texas Permanent School Fund owned 0.07% []

Transcript Daily | May 12, 2021

Strs Ohio Cuts Stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

Strs Ohio lessened its holdings in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 59.2% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 9,214 shares of the companys stock after selling 13,343 shares during the period. Strs Ohios holdings in []

Transcript Daily | May 11, 2021

Neurocrine Biosciences to Present at the 2021 RBC Global Healthcare Conference

SAN DIEGO , May 11, 2021 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the 2021 RBC Capital Markets Healthcare Conference at 10:55 a.m. Eastern Time on Tuesday May 18, 2021 . Matt Abernethy , Chief Financial Officer, and Eiry Roberts, Chief Medical Officer, will

Neurocrine Biosciences | May 11, 2021


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.5836 seconds.